IDiyas

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Thomas H McLean

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 50(Granted Patents)


Location History:

  • Cambridge, MA (US) (2019 - 2022)
  • West Roxbury, MA (US) (2024)

Company Filing History:

goldMedal6 out of 18 
 
Nimbus Lakshmi, Inc.
 patents
silverMedal5 out of 6 
 
Nimbus Lakshimi, Inc.
 patents
bronzeMedal3 out of 12 
 
Relay Therapeutics, Inc.
 patents
4. 2 out of 27 
 
D.e. Shaw Research, LLC
 patents
where one patent can have more than one assignee

Years Active: 2019-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 12331056 - SHP2 phosphatase inhibitors and methods of use thereof (2025-06-17),
2. 12219327 - Substituted isoindolines as PI3K-alpha inhibitors (2025-02-04),
3. 12084447 - SHP2 phosphatase inhibitors and methods of use thereof (2024-09-10),
4. 11396508 - TYK2 inhibitors and uses thereof (2022-07-26),
5. 11220508 - TYK2 inhibitors and uses thereof (2022-01-11),
6. 11046698 - TYK2 inhibitors and uses thereof (2021-06-29),
7. 10793574 - TYK2 inhibitors and uses thereof (2020-10-06),
8. 10647713 - TYK2 inhibitors and uses thereof (2020-05-12),
9. 10577373 - TYK2 inhibitors and uses thereof (2020-03-03),
10. 10570145 - TYK2 inhibitors and uses thereof (2020-02-25),
11. 10562907 - TYK2 inhibitors and uses thereof (2020-02-18),
12. 10562906 - TYK2 inhibitors and uses thereof (2020-02-18),
13. 10508120 - TYK2 inhibitors and uses thereof (2019-12-17),
14. 10323036 - TYK2 inhibitors and uses thereof (2019-06-18),

Title: The Innovative Mind of Thomas H. McLean

Introduction

Thomas H. McLean is a distinguished inventor based in Cambridge, MA, recognized for his significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 13 patents, McLean's innovations are pivotal in advancing medical treatments and understanding of various biochemical pathways.

Latest Patents

Among his latest patents are the groundbreaking "Substituted Isoindolines as PI3K-alpha Inhibitors," which presents novel compounds and pharmaceutical compositions aimed at inhibiting the activity of PI3K-α enzymes. This patent outlines methods for treating disorders associated with PI3K-α signaling, showcasing McLean's commitment to addressing critical health issues. Another notable patent is the "SHP2 Phosphatase Inhibitors and Methods of Use Thereof," which details innovative compounds and their therapeutic applications in inhibiting SHP2 phosphatase activity. These disclosures hold promise for treating disorders linked to SHP2 deregulation, reflecting the forward-thinking nature of his research.

Career Highlights

Throughout his career, McLean has demonstrated exceptional ingenuity and dedication to scientific research. He has worked at Nimbus Lakshmi, Inc. and Nimbus Lakshimi, Inc., where he focused on the development of novel pharmaceutical compounds. His work has not only enriched his own practice but has also set a benchmark for innovation within the pharmaceutical industry.

Collaborations

Thomas H. McLean has collaborated with various experts in his field, including peers like Jeremy Robert Greenwood and Craig E. Masse. These collaborations have been instrumental in furthering his research and expanding the impact of his ground-breaking inventions.

Conclusion

In conclusion, Thomas H. McLean stands out as a prominent figure in the realm of pharmaceutical innovation. His 13 patents, focused on critical medical advancements, underscore his role as a leading inventor in the industry. McLean's work continues to inspire future generations of innovators committed to improving healthcare through scientific exploration and discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…